Inclusion Criteria:

          -  Patients must have histologically confirmed soft tissue sarcoma with evidence of
             metastatic or unresectable disease.

          -  Patients must have measurable disease by RECIST 1.1.

          -  Up to 32 prior cytotoxic chemotherapy regimens in the metastatic setting are allowed.
             Adjuvant chemotherapy or targeted therapy will not be considered a prior line of
             treatment.

          -  Age ≥18 years.

          -  ECOG performance status ≤2 (Karnofsky ≥60%).

          -  Life expectancy of greater than 12 weeks.

          -  Patients must have normal organ and marrow function as defined below:

               -  leukocytes ≥3,000/µL

               -  absolute neutrophil count ≥1,500/µL

               -  platelets ≥100,000/µL

               -  total bilirubin within normal institutional limits

               -  AST(SGOT)/ALT(SGPT) ≤1.5 X institutional upper limit of normal (ULN)

               -  creatinine ≤1.5 X institutional upper limit of normal (ULN)

          -  Peripheral neuropathy, if present, should be ≤grade 1.

          -  Women of Child bearing potential MUST use contraceptives.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  The following specific histologic subtypes of soft tissue sarcomas will be excluded:
             GIST, Kaposi's sarcoma, mesothelioma, dermatofibrosarcoma, chordoma, alveolar
             soft-part sarcoma. Also, all bone sarcomas are excluded including Ewing's sarcoma,
             osteosarcoma, GIST, low grade chondrosarcoma, and chordoma.

          -  Patients who have had treatment with chemotherapy or radiotherapy within 4 weeks (6
             weeks for nitrosoureas or mitomycin C) prior to starting study treatment or those who
             have not recovered from adverse events due to agents administered more than 4 weeks
             earlier.

          -  Patients who are receiving any other investigational agents.

          -  Patients with known brain metastases.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to gemcitabine, docetaxel, vorinostat, or G-CSF.

          -  Patients who have received and progressed on the combination of gemcitabine and
             docetaxel in the metastatic setting.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant and breastfeeding women

          -  Patients taking concomitant HDAC inhibitors.

          -  HIV-positive patients on combination antiretroviral treatment